File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients

TitleHigh incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients
Authors
Issue Date2008
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/leukres
Citation
Leukemia Research, 2008, v. 32 n. 4, p. 547-551 How to Cite?
AbstractTwenty-seven patients received the anti-CD52 monoclonal antibody alemtuzumab for hematologic malignancies and autoimmune cytopenias in a tuberculosis-endemic area. Seven patients developed mycobacterium tuberculosis (TB) infections (median: 4, 1-24, months from alemtuzumab). The actuarial 1- and 2-year incidence of TB was 31% and 45%. All patients had severe depression of lymphocyte counts subsequent to alemtuzumab treatment, and tuberculosis was extra-pulmonary in three cases. All seven patients had received prior chemotherapy/immunosuppression and tuberculosis had not occurred until alemtuzumab was administered. Patients receiving alemtuzumab in areas endemic for tuberculosis should have careful initial evaluation of TB exposure, so that prophylactic antibiotics might be administered. Tuberculosis reactivation should be considered for unexplained fever and symptoms after alemtuzumab treatment. © 2007 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/76731
ISSN
2015 Impact Factor: 2.606
2015 SCImago Journal Rankings: 1.043
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLeung, AYHen_HK
dc.contributor.authorTse, EWCen_HK
dc.contributor.authorCheung, WWWen_HK
dc.contributor.authorShek, TWHen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:24:20Z-
dc.date.available2010-09-06T07:24:20Z-
dc.date.issued2008en_HK
dc.identifier.citationLeukemia Research, 2008, v. 32 n. 4, p. 547-551en_HK
dc.identifier.issn0145-2126en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76731-
dc.description.abstractTwenty-seven patients received the anti-CD52 monoclonal antibody alemtuzumab for hematologic malignancies and autoimmune cytopenias in a tuberculosis-endemic area. Seven patients developed mycobacterium tuberculosis (TB) infections (median: 4, 1-24, months from alemtuzumab). The actuarial 1- and 2-year incidence of TB was 31% and 45%. All patients had severe depression of lymphocyte counts subsequent to alemtuzumab treatment, and tuberculosis was extra-pulmonary in three cases. All seven patients had received prior chemotherapy/immunosuppression and tuberculosis had not occurred until alemtuzumab was administered. Patients receiving alemtuzumab in areas endemic for tuberculosis should have careful initial evaluation of TB exposure, so that prophylactic antibiotics might be administered. Tuberculosis reactivation should be considered for unexplained fever and symptoms after alemtuzumab treatment. © 2007 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/leukresen_HK
dc.relation.ispartofLeukemia Researchen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAntibodies, Monoclonal - therapeutic useen_HK
dc.subject.meshAntibodies, Monoclonal, Humanizeden_HK
dc.subject.meshAntibodies, Neoplasm - therapeutic useen_HK
dc.subject.meshAntineoplastic Agents - therapeutic useen_HK
dc.subject.meshAsian Continental Ancestry Groupen_HK
dc.subject.meshCohort Studiesen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHong Kong - epidemiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunosuppressive Agentsen_HK
dc.subject.meshIncidenceen_HK
dc.subject.meshLymphoproliferative Disorders - complications - drug therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMycobacterium tuberculosis - pathogenicityen_HK
dc.subject.meshRNA, Messenger - genetics - metabolismen_HK
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_HK
dc.subject.meshTuberculosis - epidemiology - microbiology - mortalityen_HK
dc.titleHigh incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0145-2126&volume=32&issue=4&spage=547&epage=551&date=2007&atitle=High+incidence+of+tuberculosis+after+alemtuzumab+treatment+in+Hong+Kong+Chinese+patientsen_HK
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_HK
dc.identifier.emailTse, EWC:ewctse@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityLeung, AYH=rp00265en_HK
dc.identifier.authorityTse, EWC=rp00471en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.leukres.2007.06.010en_HK
dc.identifier.pmid17714782-
dc.identifier.scopuseid_2-s2.0-39049134275en_HK
dc.identifier.hkuros146168en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-39049134275&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume32en_HK
dc.identifier.issue4en_HK
dc.identifier.spage547en_HK
dc.identifier.epage551en_HK
dc.identifier.isiWOS:000254724300005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLeung, AYH=7403012668en_HK
dc.identifier.scopusauthoridTse, EWC=7005019454en_HK
dc.identifier.scopusauthoridCheung, WWW=8615134400en_HK
dc.identifier.scopusauthoridShek, TWH=7005479861en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats